The merger, backed by an oversubscribed $180 million private placement, will fund development of NOR-101, an IL-13 x IL-18 bispecific antibody entering phase 1 trials in atopic dermatitis in early 2027.
|Articles|April 12, 2022
Looking to the Future of AD Treatment
Author(s)Colleen Hall
Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment.
Advertisement
In this video, taken at the at the 4th annual Revolutionizing Atopic Dermatitis (RAD) conference being held from April 9 to 11, in Baltimore, Maryland, Brett King, MD, of Yale School of Medicine, discusses the future of atopic dermatitis treatment, noting that the addition of targeted agents is enabling better responses in patients.
Advertisement
Related to this article
Dermatitis-related adverse events vary widely across atopic dermatitis systemic trials, driven by disease fluctuation and reporting differences, informing patient counseling and flare definitions.
New review explores why eczema and ADHD often overlap in youth, highlighting sleep loss, itch-driven inflammation, plus screening and treatment tips.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series.
Advertisement
Advertisement
Trending on Dermatology Times
1
FDA Approves Baricitinib for Adolescents With Severe Alopecia Areata
2
From Mechanism to Management: Navigating Male Pattern Hair Loss and New Topical Therapies
3
Dr. Charrow Highlights Earlier Biologic Use and Deroofing in Hidradenitis Suppurativa
4
Tremfya Meets Primary, Major Secondary Endpoints in Phase 4 STAR Study of Axial PsA
5